İnfliksimab ve biyobenzerlerinin steroide refrakter şiddetli ülseratif kolitte kolektomisiz sağ kalıma etkisinin incelenmesi

Yıl 2024, Cilt: 23 Sayı: 3, 85 - 92, 25.12.2024

Fatih Eren Mehmet Refik Göktuğ , Selcan Cesur , Mehmet Kürşad Keskin , Fahri Güven Çakır Aslı Macunluoğlu Selim Gürel , Mahmut Enver Dolar

https://doi.org/10.17941/agd.1590614

Öz

Giriş ve Amaç: Ülseratif kolitli hastaların üçte biri akut şiddetli ülseratif kolit ile başvurmakta ve kortikosteroid tedavisi gerekmektedir. Çalışmada kortikosteroide yanıtsız hastalarda infliksimab ve biyobenzerlerinin kurtarma tedavisinde kolektomisiz sağ kalım üzerine etkisi araştırılmıştır. Gereç ve Yöntem: Truelove-Witts aktivite indeksine göre şiddetli kolit kriterlerini karşılayan ve intravenöz kortikosteroid tedavisine yanıtsız olması nedeniyle infliksimab kurtarma tedavisi verilen 48 hasta retrospektif olarak değerlendirildi. Klinik kötüleşme, yeni tedaviye geçilme gerekliliği ve kolektomi ihtiyacı progresyon olarak tanımlandı. Kısa süreli (3 ay) ve uzun süreli (12 ay) kolektomisiz sağ kalım primer sonlanım olarak kabul edildi. Ayrıca orijinal ve biyobenzer infliksimab etkinlik açısından karşılaştırıldı. Bulgular: 14 hastaya orijinal infliksimab, 34 hastaya biyobenzer infliksimab tedavisi verilmişti. Kısa ve uzun süreli sonlanımda hiçbir hastada kolektomi ihtiyacı saptanmadı. İki yıl ve üzerinde biyobenzer infliksimab tedavisi alan iki hastaya kolektomi uygulanmış olduğu saptandı. Progresyon varlığına göre sağ kalım sürelerinin istatistiksel olarak farklılık gösterdiği belirlendi (p < 0.001). Genel sağ kalım süresinin ise farklılık göstermediği saptandı (p > 0.05). Sonuç: Kortikosteroide refrakter şiddetli ülseratif kolitli hastalarda kolektomisiz sağ kalım için hem orijinal hem de biyobenzer infliksimab etkili bulundu.

Anahtar Kelimeler

Akut şiddetli ülseratif kolit, infliksimab, biyobenzer

The effect of infliximab and its biosimilars on colectomy-free survival in steroid refractory severe ulcerative colitis

Öz

Background and Aims: One-third of patients with acute severe ulcerative colitis necessitate corticosteroid treatment. This study aimed to evaluate the efficacy of infliximab and its biosimilars on colectomy-free survival as a rescue therapy in corticosteroid-refractory patients. Materials and Methods: This retrospective study evaluated 48 patients meeting the criteria for severe colitis according to the Truelove-Witts activity index. The study group included patients refractory to intravenous corticosteroid therapy who received rescue treatment with infliximab. Progression was defined as clinical deterioration, the need for new treatment, and the need for colectomy. The primary outcomes were short-term (3 months) and long-term (12 months) colectomy-free survival. The efficacy of originator and biosimilar infliximab was also compared. Results: Fourteen patients were treated with originator Infliximab and 34 with biosimilar infliximab. Both short-term and long-term survival outcomes showed no immediate need for colectomy. Two patients in the biosimilar infliximab group underwent total colectomy operation more than two years after treatment. Survival times was statistically different according to the presence of progression (p < 0.001). However, there was no significant difference in overall survival between the groups (p > 0.05). Conclusions: Both originator and biosimilar infliximab are effective in achieving colectomy-free survival in patients with severe ulcerative colitis refractory to corticosteroids.

Anahtar Kelimeler

Acute severe ulcerative colitis, infliximab, biosimilars

Kaynakça

• 1- da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458-67.
• 2- Monstad IL, Solberg IC, Cvancarova M, et al. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis. 2021;15(6):969-79.
• 3- Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-25.
• 4- Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am. 2020;49(4):671-88.
• 5- Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-8.
• 6- Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-53.
• 7- Burisch J, Ungaro R, Vind I, et al. Proximal disease extension in patients with limited ulcerative colitis: A Danish population-based inception cohort. J Crohns Colitis 2017;11:1200-4.
• 8- Ananthakrishnan AN, Issa M, Beaulieu DB, et al. History of medical hospitalisation predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:176-81.
• 9- Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7.
• 10- Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
• 11- Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10.
• 12- Jain S, Kedia S, Sethi T, et al. Predictors of long-term outcomes in patients with acute severe colitis: a northern Indian cohort study. J Gastroenterol Hepatol 2018;33:615-22.
• 13- Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-10.
• 14- Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med. 2019;9(1):94.
• 15- Sjöberg M, Magnuson A, Björk J, et al; Swedish Organization for the Study of Inflammatory Bowel Disease (SOIBD). Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38(4):377-87.
• 16- Jørgensen KK, Olsen IC, Goll GL, et al; NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304-16.
• 17- Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study. Gastroenterology 2005;128:1805-11.
• 18- Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis. 2016;22(12):2966-76.
• 19- Oh SJ , Lee CK, Kim YW, et al. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. Scand J Gastroenterol2019;54:976-83.
• 20- Zhang WX, Ma CY, Zhang JG, et al. Effects of cytomegalovirus infection on the prognosis of inflammatory bowel disease patients. Exp Ther Med 2016;12:3287-93.
• 21- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-7.
• 22- Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011;106:2001-8.
• 23- Ilias A, Gonczi L, Kurti Z, lakatos PL. Biosimilars in ulcerative colitis: When and for who? Best Pract Res Clin Gastroenterol. 2018;32-33:35-42.
• 24- Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol. 2019;12:1756284819842748.
• 25- Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014;8(11):1548-50.
• 26- Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45-52.
• 27- Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35-44.